Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,900.00-1.51%ETH$2,404.54-3.20%GOLD$4,387.30+1.26%OIL$103.71-2.00%
Smart Investors Daily
ST

NASDAQ · STTK

Shattuck Labs, Inc.

Healthcare · Biotechnology

$5.97

Down-$0.23 (-3.71%)

Updated Sep 16, 2026, 10:47 AM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
154.73M
P/E ratio
-4.25
Dividend yield
0.00%
52-week range
$1.70 – $8.33
Volume
895.24K
Avg. volume
297.21K

Price performance

STTK price history

1M range · 20 trading sessions · Daily adjusted prices

STTK closed at $5.97 after 20 trading sessions, down 19.87% for the selected period.

Last close
$5.97
Period change
-19.87%
Period low
$5.97
Period high
$8.06
Daily close
View OHLC price history
STTK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$6.18$6.23$5.911$5.97895.24K
Sep 14, 2026$6.21$6.265$6.085$6.20821.91K
Sep 11, 2026$6.24$6.36$6.07$6.20846.93K
Sep 10, 2026$6.21$6.345$6.10$6.151.17M
Sep 9, 2026$6.39$6.57$6.245$6.331.06M
Sep 8, 2026$6.80$6.86$6.47$6.501M
Sep 4, 2026$6.84$6.88$6.6742$6.79677.76K
Sep 3, 2026$6.96$7.045$6.83$6.96563.93K
Sep 2, 2026$6.91$7.28$6.77$6.91583.53K
Sep 1, 2026$6.90$7.06$6.76$6.87639.62K
Aug 31, 2026$6.98$7.04$6.83$7.01751.23K
Aug 28, 2026$7.55$7.59$7.035$7.04623.14K
Aug 27, 2026$7.86$7.93$7.63$7.65543.53K
Aug 26, 2026$8.03$8.04$7.7901$7.90581.84K
Aug 25, 2026$8.01$8.15$7.93$8.06869.8K
Aug 24, 2026$7.66$8.02$7.50$7.902.06M
Aug 21, 2026$7.35$7.55$7.25$7.53475.59K
Aug 20, 2026$7.56$7.56$7.24$7.25419.7K
Aug 19, 2026$7.69$7.88$7.47$7.66767.47K
Aug 18, 2026$7.32$7.47$7.04$7.45517.15K

Latest STTK news

The latest Smart Investors Daily articles mentioning STTK.

Stock researchCompany · Overview

STTK research

Overview

Company profile and research snapshot.

Company profile

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$4.00
Implied upside
—
Analysts
12
STTK recent ratings
DateFirmRatingTarget
Aug 24, 2026Raymond JamesStrong Buy—
Aug 11, 2026HC Wainwright & Co.Buy—
Jul 24, 2026JP MorganOverweight—
Jul 20, 2026Leerink PartnersOutperform—
Jun 9, 2026CitigroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences: Conference Details Wells Farg

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By